메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Arihant Jain (Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh 160012, India) Aditya Jandial (Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh 160012, India) Thenmozhi Mani (Department of Biostatistics, CMC, Vellore, Hematology, India) Kamal Kishore (Department of Biostatistics, PGIMER, Chandigarh, India) Charanpreet Singh (Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh 160012, India) Deepesh Lad (Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh 160012, India) Gaurav Prakash (Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh 160012, India) Alka Khadwal (Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh 160012, India) Reena Das (Department of Hematology, PGIMER, Chandigarh, India) Neelam Varma (Department of Hematology, PGIMER, Chandigarh, India) Subhash Varma (Department of Hematology, PGIMER, Chandigarh, India) Pankaj Malhotra (Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh 160012, India)
저널정보
대한혈액학회 Blood Research Blood Research Vol.59 No.1
발행연도
2024.3
수록면
6 - 6 (1page)
DOI
10.1007/s44313-024-00003-z

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background The standard dose (SD) of horse anti-thymocyte globulin (hATG) ATGAM (Pfizer, USA) or its biosimilar thymogam (Bharat Serum, India) for the treatment of Aplastic Anemia (AA) is 40 mg/kg/day for 4 days in combination with cyclosporine. Data on the impact of hATG dose on long-term outcomes are limited. Here, we describe our comparative experience using 25 mg/kg/day (low-dose [LD]) hATG for 4 days with SD for the treatment of AA. Methods We retrospectively studied patients with AA (age > 12 years) who received two doses of hATG combined with cyclosporine. Among 93 AA patients who received hATG, 62 (66.7%) and 31 (33.3%) patients received LD and SD hATG with cyclosporine, respectively. Among these,seventeen(18.2%) patients also received eltrombopag with hATG and cyclosporine. Overall response rates [complete response (CR) and partial response (PR)] of LD and SD hATG groups at 3 months (50% vs. 48.4%; p = 0.88), 6 months (63.8% vs. 71.4%; p = 0.67), and 12 months (69.6% vs. 79.2%; p = 0.167) were comparable. The mean (Standard Deviation) 5-year Kaplan–Meier estimate of overall survival and event-free survival was 82.1 (4.6)% and 70.9 (5.5)% for the study population. The mean (standard deviation) 5-year Kaplan–Meier estimate of overall survival and event-free survival of those who received LD hATG versus SD hATG dose was 82.9 (5·3)% versus 74.8 (10·3)% (P = 0·439), and 75.2 (6.2)% versus 61.4(11.2)% (P = 0·441). Conclusion Our study revealed that the response rates of patients with AA and LD were similar to those of patients with SD to hATG combined with cyclosporine in a real-world setting.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0